Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

The interaction between SPARC and GRP78 interferes with ER stress signaling and potentiates apoptosis via PERK/eIF2α and IRE1α/XBP-1 in colorectal cancer.

Chern YJ, Wong JCT, Cheng GSW, Yu A, Yin Y, Schaeffer DF, Kennecke HF, Morin G, Tai IT.

Cell Death Dis. 2019 Jun 26;10(7):504. doi: 10.1038/s41419-019-1687-x.

2.

Prognostic effect of sidedness in early stage versus advanced colon cancer.

Kennecke HF, Yin Y, Davies JM, Speers CH, Cheung WY, Lee-Ying R.

Health Sci Rep. 2018 Jun 27;1(8):e54. doi: 10.1002/hsr2.54. eCollection 2018 Aug.

3.

Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer.

Tsang ES, Wong HL, Wang Y, Renouf DJ, Cheung WY, Lim HJ, Gill S, Loree JM, Kennecke HF.

Am J Clin Oncol. 2019 Feb;42(2):196-201. doi: 10.1097/COC.0000000000000500.

PMID:
30499841
4.

A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens.

Alcaide M, Cheung M, Bushell K, Arthur SE, Wong HL, Karasinska J, Renouf D, Schaeffer DF, McNamara S, Tertre MCD, Batist G, Kennecke HF, Karsan A, Morin RD.

J Mol Diagn. 2019 Mar;21(2):214-227. doi: 10.1016/j.jmoldx.2018.09.007. Epub 2018 Nov 23.

PMID:
30472330
5.

ASO Author Reflections: Outcomes of Appendiceal Goblet Cell Carcinoid Tumors.

Tsang ES, Kennecke HF.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):759-760. doi: 10.1245/s10434-018-6980-x. Epub 2018 Nov 21. No abstract available.

PMID:
30465217
6.

Outcomes of Surgical and Chemotherapeutic Treatments of Goblet Cell Carcinoid Tumors of the Appendix.

Tsang ES, McConnell YJ, Schaeffer DF, Lee L, Yin Y, Zerhouni S, Schaff K, Speers C, Kennecke HF.

Ann Surg Oncol. 2018 Aug;25(8):2391-2399. doi: 10.1245/s10434-018-6560-0. Epub 2018 Jun 18.

PMID:
29916007
7.

Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer.

Loree JM, Sha A, Soleimani M, Kennecke HF, Ho MY, Cheung WY, Mulder KE, Abadi S, Spratlin JL, Gill S.

Clin Colorectal Cancer. 2018 Jun;17(2):156-163. doi: 10.1016/j.clcc.2018.01.010. Epub 2018 Feb 7.

PMID:
29486916
8.

Prognostic Factors for Locoregional Recurrence in Neuroendocrine Tumors of the Rectum.

Tsang ES, McConnell YJ, Schaeffer DF, Yin Y, Speers CH, Kennecke HF.

Dis Colon Rectum. 2018 Feb;61(2):187-192. doi: 10.1097/DCR.0000000000000996.

PMID:
29337773
9.

Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer.

Loree JM, Tan SK, Lafond LM, Speers CH, Kennecke HF, Cheung WY.

Clin Colorectal Cancer. 2018 Mar;17(1):65-72. doi: 10.1016/j.clcc.2017.10.011. Epub 2017 Oct 23.

PMID:
29153430
10.

Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.

Wong HL, Yang KC, Shen Y, Zhao EY, Loree JM, Kennecke HF, Kalloger SE, Karasinska JM, Lim HJ, Mungall AJ, Feng X, Davies JM, Schrader K, Zhou C, Karsan A, Jones SJM, Laskin J, Marra MA, Schaeffer DF, Gorski SM, Renouf DJ.

Cold Spring Harb Mol Case Stud. 2018 Feb 1;4(1). pii: a002329. doi: 10.1101/mcs.a002329. Print 2018 Feb.

11.

Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration.

Segelov E, Chan D, Lawrence B, Pavlakis N, Kennecke HF, Jackson C, Law C, Singh S.

J Glob Oncol. 2016 Oct 12;3(4):380-388. doi: 10.1200/JGO.2016.006916. eCollection 2017 Aug.

12.

Impact of Duration of Neoadjuvant Radiation on Rectal Cancer Survival: A Real World Multi-center Retrospective Cohort Study.

Abdel-Rahman O, Kumar A, Kennecke HF, Speers CH, Cheung WY.

Clin Colorectal Cancer. 2018 Mar;17(1):e21-e28. doi: 10.1016/j.clcc.2017.06.003. Epub 2017 Jun 23.

PMID:
28709877
13.

Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2.

Weiswald LB, Hasan MR, Wong JCT, Pasiliao CC, Rahman M, Ren J, Yin Y, Gusscott S, Vacher S, Weng AP, Kennecke HF, Bièche I, Schaeffer DF, Yapp DT, Tai IT.

Mol Cancer Ther. 2017 Oct;16(10):2292-2303. doi: 10.1158/1535-7163.MCT-16-0666. Epub 2017 Jun 29.

14.

The utility of abbreviated patient-reported outcomes for predicting survival in early stage colorectal cancer.

Hsu T, Speers CH, Kennecke HF, Cheung WY.

Cancer. 2017 May 15;123(10):1839-1847. doi: 10.1002/cncr.30511. Epub 2017 Jan 12.

15.

Impact of Postoperative Adjuvant Chemotherapy Following Long-course Chemoradiotherapy in Stage II Rectal Cancer.

Loree JM, Kennecke HF, Lee-Ying RM, Goodwin RA, Powell ED, Tang PA, Price Hiller JA, Vickers MM, Cheung WY.

Am J Clin Oncol. 2018 Jul;41(7):643-648. doi: 10.1097/COC.0000000000000342.

PMID:
27819876
16.

Patterns of practice with third-line anti-EGFR antibody for metastatic colorectal cancer.

Ho MY, Renouf DJ, Cheung WY, Lim HJ, Speers CH, Zhou C, Kennecke HF.

Curr Oncol. 2016 Oct;23(5):329-333. Epub 2016 Oct 25.

17.

Impact of Travel Distance and Urban-Rural Status on the Multidisciplinary Management of Rectal Cancer.

Loree JM, Javaheri KR, Lefresne SV, Speers CH, Ruan JY, Chang JT, Brown CJ, Kennecke HF, Olson RA, Cheung WY.

J Rural Health. 2017 Sep;33(4):393-401. doi: 10.1111/jrh.12219. Epub 2016 Oct 7.

PMID:
27717002
18.

Population-Based Patterns and Factors Associated With Underuse of Palliative Systemic Therapy in Elderly Patients With Metastatic Colon Cancer.

Chan M, Hugh-Yeun K, Gresham G, Speers CH, Kennecke HF, Cheung WY.

Clin Colorectal Cancer. 2017 Jun;16(2):147-153. doi: 10.1016/j.clcc.2016.08.004. Epub 2016 Aug 30.

PMID:
27670894
19.

A Comparison of Survival by Site of Metastatic Resection in Metastatic Colorectal Cancer.

Lee-Ying R, Bernard B, Gresham G, Chen L, Speers C, Kennecke HF, Lim HJ, Cheung WY, Renouf DJ.

Clin Colorectal Cancer. 2017 Jun;16(2):e23-e28. doi: 10.1016/j.clcc.2016.07.018. Epub 2016 Aug 9.

PMID:
27637559
20.

Effect of Adjuvant Chemotherapy on Stage II Rectal Cancer Outcomes After Preoperative Short-Course Radiotherapy.

Loree JM, Kennecke HF, Renouf DJ, Lim HJ, Vickers MM, Speers CH, Cheung WY.

Clin Colorectal Cancer. 2016 Dec;15(4):352-359.e1. doi: 10.1016/j.clcc.2016.04.003. Epub 2016 May 7.

PMID:
27265355
21.

Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).

Barry GS, Cheang MC, Chang HL, Kennecke HF.

Oncotarget. 2016 Apr 5;7(14):18953-64. doi: 10.18632/oncotarget.8006.

22.

Case Report of Cirrhosis following Yttrium-90 Radioembolization for Pancreatic Neuroendocrine Liver Metastases.

Loree JM, Hiruki T, Kennecke HF.

Case Rep Oncol. 2016 Jan 30;9(1):76-82. doi: 10.1159/000443985. eCollection 2016 Jan-Apr.

23.

Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.

Ko JJ, Kennecke HF, Lim HJ, Renouf DJ, Gill S, Woods R, Speers C, Cheung WY.

Clin Colorectal Cancer. 2016 Jun;15(2):179-85. doi: 10.1016/j.clcc.2015.09.002. Epub 2015 Sep 30.

PMID:
26520019
24.

Impact of Weight Changes After the Diagnosis of Stage III Colon Cancer on Survival Outcomes.

Vergidis J, Gresham G, Lim HJ, Renouf DJ, Kennecke HF, Ruan JY, Chang JT, Cheung WY.

Clin Colorectal Cancer. 2016 Mar;15(1):16-23. doi: 10.1016/j.clcc.2015.07.002. Epub 2015 Jul 26.

PMID:
26281943
25.

Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.

Dascalu B, Kennecke HF, Lim HJ, Renouf DJ, Ruan JY, Chang JT, Cheung WY.

Support Care Cancer. 2016 Feb;24(2):799-805. doi: 10.1007/s00520-015-2846-y. Epub 2015 Jul 17.

PMID:
26184500
26.

Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.

Ho MY, Kennecke HF, Renouf DJ, Cheung WY, Lim HJ, Gill S.

Am J Clin Oncol. 2017 Dec;40(6):552-554. doi: 10.1097/COC.0000000000000205.

PMID:
26165420
27.

Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.

Kumar A, Peixoto RD, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Speers CH, Cheung WY.

Clin Colorectal Cancer. 2015 Dec;14(4):262-8.e1. doi: 10.1016/j.clcc.2015.05.010. Epub 2015 Jun 6.

PMID:
26123496
28.

Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer.

Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF.

Cancer Med. 2015 Aug;4(8):1171-7. doi: 10.1002/cam4.459. Epub 2015 Apr 18.

29.

Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).

Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, Lim HJ, Hezel AF, Vaccaro GM, Blanke CD.

Cancer. 2015 Jul 1;121(13):2193-7. doi: 10.1002/cncr.29363. Epub 2015 Mar 30.

30.
31.

Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.

Peixoto RD, Kumar A, Speers C, Renouf D, Kennecke HF, Lim HJ, Cheung WY, Melosky B, Gill S.

Clin Colorectal Cancer. 2015 Mar;14(1):25-30. doi: 10.1016/j.clcc.2014.10.002. Epub 2014 Nov 4.

PMID:
25465343
32.

Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.

Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, Speers C, Cheung WY.

Cancer. 2015 Feb 15;121(4):527-34. doi: 10.1002/cncr.29072. Epub 2014 Oct 20.

33.

Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs.

Peixoto RD, Noonan KL, Pavlovich P, Kennecke HF, Lim HJ.

J Gastrointest Oncol. 2014 Aug;5(4):247-52. doi: 10.3978/j.issn.2078-6891.2014.019.

34.

Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.

Thind G, Johal B, Follwell M, Kennecke HF.

Radiat Oncol. 2014 May 29;9:124. doi: 10.1186/1748-717X-9-124.

35.

Association between palliative resection of the primary tumor and overall survival in a population-based cohort of metastatic colorectal cancer patients.

Gresham G, Renouf DJ, Chan M, Kennecke HF, Lim HJ, Brown C, Cheung WY.

Ann Surg Oncol. 2014 Nov;21(12):3917-23. doi: 10.1245/s10434-014-3797-0. Epub 2014 May 24.

PMID:
24859937
36.

Surgical management of node-positive prostate cancer: perspectives from breast oncology.

Kennecke HF, Keyes M.

Eur Urol. 2014 Aug;66(2):202-3. doi: 10.1016/j.eururo.2013.09.007. Epub 2013 Sep 13. No abstract available.

PMID:
24094573
37.

Screening intervention to identify eligible patients and improve accrual to phase II-IV oncology clinical trials.

Chen L, Grant J, Cheung WY, Kennecke HF.

J Oncol Pract. 2013 Jul;9(4):e174-81. doi: 10.1200/JOP.2012.000763. Epub 2013 Mar 5.

38.

Nucleophosmin 1, upregulated in adenomas and cancers of the colon, inhibits p53-mediated cellular senescence.

Wong JC, Hasan MR, Rahman M, Yu AC, Chan SK, Schaeffer DF, Kennecke HF, Lim HJ, Owen D, Tai IT.

Int J Cancer. 2013 Oct 1;133(7):1567-77. doi: 10.1002/ijc.28180. Epub 2013 Apr 30.

39.

Body mass index and body surface area and their associations with outcomes in stage II and III colon cancer.

Alipour S, Kennecke HF, Woods R, Lim HJ, Speers C, Brown CJ, Gill S, Renouf DJ, Cheung WY.

J Gastrointest Cancer. 2013 Jun;44(2):203-10. doi: 10.1007/s12029-012-9472-4.

PMID:
23264206
40.

Impact of routine pathology review on treatment for node-negative breast cancer.

Kennecke HF, Speers CH, Ennis CA, Gelmon K, Olivotto IA, Hayes M.

J Clin Oncol. 2012 Jun 20;30(18):2227-31. doi: 10.1200/JCO.2011.38.9247. Epub 2012 May 7.

PMID:
22564990
41.

Adjuvant chemotherapy for stage III colon cancer: does timing matter?

Czaykowski PM, Gill S, Kennecke HF, Gordon VL, Turner D.

Dis Colon Rectum. 2011 Sep;54(9):1082-9. doi: 10.1097/DCR.0b013e318223c3d6.

PMID:
21825887
42.

Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?

Yerushalmi R, Tyldesley S, Woods R, Kennecke HF, Speers C, Gelmon KA.

Ann Oncol. 2012 Apr;23(4):876-81. doi: 10.1093/annonc/mdr326. Epub 2011 Aug 2.

PMID:
21810730
43.

Effectiveness of a letter notification program for women with early-stage breast cancer eligible for extended adjuvant letrozole.

McArthur HL, Gelmon KA, Olivotto IA, Speers CH, Ellard SL, O'Reilly SE, Kennecke HF.

J Clin Oncol. 2009 Mar 20;27(9):1388-93. doi: 10.1200/JCO.2008.18.4127. Epub 2009 Feb 23.

PMID:
19237634
44.

Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.

Kennecke HF, Olivotto IA, Speers C, Norris B, Chia SK, Bryce C, Gelmon KA.

Ann Oncol. 2007 Jan;18(1):45-51. Epub 2006 Oct 9.

PMID:
17030545

Supplemental Content

Loading ...
Support Center